Global Non-Hodgkin Lymphoma Therapeutics Market - Global Industry Size, Share, Trends, Competition, Opportunity, and Forecast, By Therapy Type (Chemotherapy, Radiation Therapy, Targeted Therapy, Immunotherapy (incl. CAR-T, Bispecifics), Other Therapies), By Cell Type (B-cell Lymphomas, T-cell Lymphomas), By Treatment Line (First-line, Second-line, Third-line & Refractory), By Region, By Company 2021-2031F 2021-2031F

Key Insights	Details
Forecast Period	2026 - 2031
Market Size (2025)	USD 11.09 Billion
CAGR (2026-2031)	6.93%
Fastest Growing Segment	T-cell lymphomas (fastest 7.93% CAGR to 2031)
Largest Market	North America
Market Size (2031)	USD 16.58 Billion

Market Overview

The Global Non-Hodgkin Lymphoma Therapeutics Market is expected to grow from USD 11.09 Billion in 2025 to USD 16.58 Billion by 2031 at a 6.93% CAGR. Non-Hodgkin Lymphoma therapeutics encompass a range of pharmaceutical interventions designed to treat malignant neoplasms originating from lymphocytes within the lymphatic system, utilizing various modalities such as chemotherapy, immunotherapy, and targeted therapies. The market's expansion is fundamentally driven by the increasing global incidence of Non-Hodgkin Lymphoma, particularly within aging populations, alongside continuous advancements in diagnostic capabilities enabling earlier and more precise disease detection. Further impetus comes from robust investment in oncology research and development; according to PhRMA, its member companies invested over $110 billion in research and development in 2025.

A significant challenge impeding market growth, however, remains the substantial cost associated with novel therapeutic agents and complex treatment regimens. This economic burden can limit patient access and pose considerable strain on healthcare systems globally, thereby hindering wider adoption of advanced Non-Hodgkin Lymphoma treatments.

Key Market Drivers

Advancements in Immunotherapy and Targeted Therapies Drive NHL Market Growth
Advancements in immunotherapy and targeted therapies significantly propel the Global Non-Hodgkin Lymphoma Therapeutics Market by offering precise and effective treatment modalities. These innovative approaches leverage specific biological pathways to target cancer cells, often improving response rates and reducing systemic toxicities. The continuous evolution in understanding the molecular intricacies of non-Hodgkin lymphoma subtypes drives novel agent development. For instance, according to Roche's 9M 2026 Sales Report, October 2026, sales of its targeted therapy Polivy surged 24% to CHF 1.3 billion, driven by strong uptake in first-line diffuse large B-cell lymphoma indications, underscoring its commercial success and clinical adoption. These therapeutic innovations address critical unmet needs, particularly in patients with aggressive disease forms.

CAR-T and Bispecific Antibodies Accelerate NHL Therapeutics Expansion
The growing demand for CAR-T cell therapies and bispecific antibodies represents another pivotal driving factor, reshaping the treatment landscape for relapsed and refractory non-Hodgkin lymphoma. These highly specialized immunotherapies harness the patient's immune system or engineered antibodies to directly engage and eliminate cancer cells, often providing durable responses in heavily pre-treated individuals. The expansion of indications for these treatments across various NHL subtypes, coupled with ongoing clinical trials, further fuels market expansion. Reflecting this robust demand, according to Trefis, November 2026, Bristol Myers Squibb's CAR-T cell therapy Breyanzi saw its revenue for the third quarter of 2026 rise 48% to $526 million. Overall, the global oncology market, encompassing non-Hodgkin lymphoma therapeutics, demonstrates continued activity. According to AbbVie's Third-Quarter 2026 Financial Results, October 2026, global net revenues from its oncology portfolio reached $1.696 billion.

Download Free Sample Report

Key Market Challenges

Economic burden restricts patient access and slows market growth for NHL therapeutics.
The substantial cost associated with novel therapeutic agents and complex treatment regimens significantly impedes the growth of the Global Non-Hodgkin Lymphoma Therapeutics Market. This economic burden directly limits patient access to advanced treatments, particularly in regions with constrained healthcare budgets or insufficient insurance coverage. The high pricing of specialized drugs and the intricate nature of their administration impose considerable financial strain on healthcare systems globally. This pressure often results in delayed treatment initiation, restricted formulary inclusion, or the continued reliance on older, less effective therapies. According to the American Hospital Association's "Costs of Caring" report, hospital drug expenses in the U.S. increased by 13.6% in 2025, indicating the substantial financial demands on healthcare providers. This financial barrier inherently restricts the widespread adoption of innovative Non-Hodgkin Lymphoma therapeutics, thereby directly curtailing the market's overall expansion and the reach of these potentially transformative interventions.

Key Market Trends

Shift to Outpatient-Ready Therapies and Novel Delivery Formats
Advancements in outpatient-ready therapeutic options represent a significant trend shaping the Global Non-Hodgkin Lymphoma Therapeutics Market by enhancing patient accessibility and reducing the burden on healthcare infrastructure. The shift towards more convenient administration methods, such as subcutaneous formulations and oral therapies, allows for treatment outside traditional inpatient settings, improving patient quality of life and potentially lowering overall treatment costs. This approach reflects an industry-wide effort to streamline therapy delivery. For instance, according to Bristol Myers Squibb's Third Quarter Financial Results for 2026, approximately 17% of its intravenous business for a key growth portfolio medicine has converted to a subcutaneous formulation, with the company aiming for 30% to 40% conversion. Such innovations in drug delivery are crucial as complex treatment regimens become more prevalent, underscoring their influence on future NHL therapeutic development and patient management.

Personalized, Biomarker-Guided Therapies in NHL
The growing emphasis on personalized medicine approaches is another impactful trend, driving the development of highly specific therapies tailored to the unique molecular and genetic characteristics of individual non-Hodgkin lymphoma subtypes. This trend moves beyond broad-spectrum treatments, enabling more precise targeting of cancer cells, which can lead to improved efficacy and reduced toxicity. Deeper insights into disease biology facilitate the identification of biomarkers that guide treatment selection, optimizing therapeutic outcomes for specific patient populations. Illustrating this focus, according to AbbVie's Third-Quarter 2026 Financial Results, its targeted therapy Venclexta, a BCL-2 inhibitor, achieved global net revenues of $803 million, marking a 10.7% increase. This growth highlights the commercial success and clinical adoption of therapies aligned with personalized medicine principles within the oncology landscape, directly influencing the NHL market.

Segmental Insights

Growth Drivers in the T-Cell Lymphomas Segment
The T-cell lymphomas segment represents a key growth area within the Global Non-Hodgkin Lymphoma Therapeutics Market. This rapid expansion is primarily driven by the increasing global incidence of aggressive T-cell lymphoma subtypes, which underscores a persistent high unmet medical need and suboptimal outcomes from conventional chemotherapy regimens. Consequently, there is a heightened demand for innovative and effective treatments. Significant advancements in targeted therapies, including immunotherapies such as CAR-T cells, monoclonal antibodies, and precision medicines, are transforming the treatment landscape by offering more effective options for patients. Furthermore, a supportive regulatory environment and the increasing introduction of new products and approvals contribute to accelerating market growth, alongside improved molecular diagnostics facilitating earlier and more accurate disease detection.

Regional Insights

North America Leads the Global Non-Hodgkin Lymphoma Therapeutics Market
North America consistently leads the global Non-Hodgkin Lymphoma Therapeutics Market, primarily driven by its advanced healthcare infrastructure and significant investments in research and development. The region benefits from a robust regulatory environment, with the U.S. Food and Drug Administration (FDA) facilitating the approval and commercialization of innovative therapies. Furthermore, a high incidence of Non-Hodgkin Lymphoma, coupled with the early adoption of advanced treatment modalities like immunotherapies and targeted therapies, underpins this market dominance. The strong presence of major pharmaceutical companies and comprehensive reimbursement policies also ensures broad patient access to novel therapeutics, cementing North America's position.

Recent Developments

• In December 2025, Bristol Myers Squibb presented updated data at the American Society of Hematology annual meeting concerning its investigational BCL6-targeting ligand-directed degrader, BMS-986458. The results from a dose-escalation study in heavily pre-treated patients with relapsed or refractory non-Hodgkin lymphoma, including diffuse large B-cell lymphoma and follicular lymphoma, demonstrated promising preliminary efficacy and acceptable tolerability. This breakthrough research indicates continued development for BMS-986458 as a potential monotherapy or combination therapy within the evolving Global Non-Hodgkin Lymphoma Therapeutics Market.
• In January 2025, Acalabrutinib (Calquence®) received U.S. Food and Drug Administration approval for the treatment of previously untreated mantle cell lymphoma, an aggressive form of non-Hodgkin lymphoma. Concurrently, the drug's conditional approval for mantle cell lymphoma after at least one prior therapy was converted to full approval. This milestone represents a vital new product launch in the Global Non-Hodgkin Lymphoma Therapeutics Market, offering patients a BTK inhibitor-based option, either as monotherapy or in combination, for first-line treatment or after relapse.
• In May 2024, Bristol Myers Squibb announced that the U.S. Food and Drug Administration granted approval for lisocabtagene maraleucel (Breyanzi), a CD19-directed CAR T-cell therapy, for adult patients with relapsed or refractory mantle cell lymphoma. This expanded indication is crucial for the Global Non-Hodgkin Lymphoma Therapeutics Market, as Breyanzi is now approved to treat four distinct subtypes of non-Hodgkin lymphoma, including large B-cell lymphoma and follicular lymphoma. This approval provides an additional advanced therapeutic option for patients with aggressive forms of the disease.
• In March 2024, the U.S. Food and Drug Administration approved the combination of Brukinsa (zanubrutinib) and Gazyva (obinutuzumab) for adult patients with relapsed or refractory follicular lymphoma who had received two or more prior systemic therapies. This approval, a significant development in the Global Non-Hodgkin Lymphoma Therapeutics Market, followed positive outcomes from the BGB-3111-212 (ROSEWOOD) trial, which demonstrated improved overall response rates and duration of response compared to Gazyva monotherapy. The combination therapy offers a new treatment option for patients facing this challenging subtype of non-Hodgkin lymphoma.

Key Market Players

• AstraZeneca PLC
• Bayer AG
• F. Hoffmann La-Roche Ltd
• Seagen Inc
• Gilead Sciences Inc. / Kite Pharma
• Roche
• Novartis
• Bristol-Myers Squibb
• Takeda Pharmaceuticals
• Janssen Biotech / Johnson & Johnson

By Therapy Type	By Cell Type	By Treatment Line	By Region
Chemotherapy Radiation Therapy Targeted Therapy Immunotherapy (incl. CAR-T, Bispecifics) Other Therapies	B-cell Lymphomas T-cell Lymphomas	First-line Second-line Third-line & Refractory	North America Europe Asia Pacific South America Middle East & Africa

Report Scope:

In this report, the Global Non-Hodgkin Lymphoma Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Non-Hodgkin Lymphoma Therapeutics Market, By Therapy Type:

• Chemotherapy
• Radiation Therapy
• Targeted Therapy
• Immunotherapy (incl. CAR-T, Bispecifics)
• Other Therapies

• Non-Hodgkin Lymphoma Therapeutics Market, By Cell Type:

• B-cell Lymphomas
• T-cell Lymphomas

• Non-Hodgkin Lymphoma Therapeutics Market, By Treatment Line:

• First-line
• Second-line
• Third-line & Refractory

• Non-Hodgkin Lymphoma Therapeutics Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• France
• United Kingdom
• Italy
• Germany
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE